PRESS RELEASE published on 06/17/2024 at 07:00, 2 years 2 months ago Informations privilégiées / Autres communiqués Innate Pharma présente de nouveaux résultats sur l'essai de phase 1/2 mené par Sanofi évaluant le NK Cell Engager SAR443579/IPH6101 dans divers cancers du sang lors du congrès annuel de l'EHA 2024 Étude De Phase 1/2 Innate Pharma NK Cell Engager SAR443579/IPH6101 Cancers Du Sang
PRESS RELEASE published on 06/17/2024 at 07:00, 2 years 2 months ago Inside Information / Other news releases Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial, showing promising clinical efficacy and safety in patients with R/R AML Sanofi Innate Pharma Blood Cancer NK Cell Engager Phase 1/2 Trial
BRIEF published on 05/28/2024 at 07:05, 2 years 3 months ago Innate Pharma annonce sa participation à de prochaines conférences investisseurs Immunothérapie Santé Conférences Investisseurs Innate Pharma Biotechnologies
BRIEF published on 05/28/2024 at 07:05, 2 years 3 months ago Innate Pharma announces its participation in upcoming investor conferences Biotechnology Investor Conferences Immunotherapy Health Innate Pharma
PRESS RELEASE published on 05/28/2024 at 07:00, 2 years 3 months ago Informations privilégiées / Autres communiqués Innate Pharma annonce sa participation à des conférences investisseurs mondiales à venir. Détails des conférences et objectif de la société biotechnologique axée sur les immunothérapies contre le cancer Biotechnologie Immunothérapie Cancer Conférences Investisseurs Innate Pharma
BRIEF published on 05/23/2024 at 22:05, 2 years 3 months ago Résultats de l'Assemblée Générale Mixte d'Innate Pharma Assemblée Générale Conseil De Surveillance Innate Pharma Résultats De Vote
BRIEF published on 05/23/2024 at 22:05, 2 years 3 months ago Results of the Combined General Meeting of Innate Pharma Voting Results Supervisory Board General Assembly Innate Pharma
PRESS RELEASE published on 05/23/2024 at 22:00, 2 years 3 months ago Informations privilégiées / Autres communiqués Innate Pharma annonce les résultats de l'Assemblée générale mixte du 23 mai 2024 avec réélection des membres du Conseil de Surveillance. Détails disponibles en ligne Résultats Conseil De Surveillance Assemblée Générale Mixte Innate Pharma Biotechnologies
PRESS RELEASE published on 05/23/2024 at 22:00, 2 years 3 months ago Inside Information / Other news releases Innate Pharma announces the voting results of its 2024 AGM. Quorum at 44.92%. Re-election of two Supervisory Board members. Details available on company's website Voting Results Supervisory Board Quorum 2024 AGM Innate Pharma
BRIEF published on 05/21/2024 at 07:05, 2 years 3 months ago Clarification sur le statut du traitement SAR443579 par Innate Pharma FDA Sanofi Innate Pharma SAR443579 Fast Track
Published on 09/12/2026 at 02:35, 11 hours 29 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 4 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 59 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 39 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 4 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 33 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 49 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 53 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 19 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 48 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
